HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Cognoptix licenses AD detection technology
Cognoptix, which was known as Neuroptix until October, has exclusively licensed technology from the University of California, San Diego, which Cognoptix has developed into a non-invasive eye-scanning test for the early detection and diagnosis of Alzheimer's disease (AD). Cognoptix also revealed that it has established a Clinical Advisory Board, comprised of key opinion leaders from among the worldwide neuroscience community.

The Cognoptix Sapphire II system consists of a laser-based reading device and consumable ophthalmic ointment. The eye exam can be given by a general practitioner and only takes a few minutes to achieve a result. The Cognoptix drug/device combination is a novel, early-stage diagnostic for AD designed to allow treatment before significant neuronal loss and irreversible brain damage occurs. A ligand or contrast agent and software-controlled optical instrument allows for non-invasive detection and assessment of AD by measuring the hallmark of AD, amyloid beta, in the supranuclear region of the lens of the eye. The ligand is administered to the eye as an ophthalmic ointment and a proprietary Fluorescent Ligand Scanning instrument, provides an objective and quantitative measurement of amyloid beta in the patient's lens. Significantly faster and an order of magnitude less expensive than brain imaging, the test and diagnosis can be quickly completed in any physician's office, including general practitioners.

Cognoptix has a strong and com-prehensive patent portfolio covering diagnosis of amyloid beta-based diseases via ophthalmic imaging. The patent portfolio includes issued method and device patents, as well as pending composition of matter patents. In addition to UC San Diego, exclusive licenses have been acquired from Massachusetts General Hospital and Brigham & Women's Hospital Boston.

There are more than 100 new AD drugs that are currently in various stages of research and development. The ability of the Cognoptix drug/device combination to identify and qualify patients for clinical study inclusion, as well as accurately and inexpensively track patient disease progression, may provide pharmaceutical companies with a significant competitive advantage in securing new AD drug approvals. It may also help identify and document differentiating pharmaceutical product performance attributes in Phase IV studies. The technology is currently in clinical trials.

Laura Attwood
Editor, Diagnostics Focus

Click here for the complete issue.

NEWS CRUNCH  
news Collaboration is Cure for Better Global Health Outcomes, UK-India Experts Say
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy